SECTIONS
SUBSCRIBE
Managed Care

Search form

  • News
  • Politics & policy
  • Drug management
  • Payers
  • Providers
  • Current Issue
  • More
    • Past issues
    • Value-Based Care
    • Profiles
    • Conversations
    • Tomorrow's Medicine
    • Original research
    • Pharm D Corner
    • Viewpoints
    • Legislation & regulation
    • Contact Us

Most Popular

New Blood Test Can Aid in Evaluation of Concussion in Adults

The FDA has permitted marketing of the first blood test to evaluate mild traumatic brain injury (mTBI), commonly referred to as concussion, in adults. The FDA reviewed and authorized the Banyan Brain Trauma Indicator (Banyan Biomarkers, Inc.) in less than six months as part of its Breakthrough Devices…
Read more

Shire’s HAE Candidate Boosted by New Phase 3 Data

Newly released phase 3 results have shown that lanadelumab, Shire plc’s experimental hereditary angioedema (HAE) drug, reduced monthly attack rates and improved quality of life compared with placebo. Recently presented at the 2018 American Academy of Allergy, Asthma, and Immunology meeting, the data…
Read more

Febuxostat Increases Death Risk for Gout Patients With Heart Disease, Study Finds

A large study of cardiovascular events in gout patients taking one of two medications to prevent excess build-up of uric acid has found that one of the drugs, febuxostat (Uloric, Takeda), increased the risk of death for those with heart disease compared with the other drug, allopurinol. Yet the two…
Read more

Trulicity Aids Diabetes Control When Added to an SGLT-2 Inhibitor

Dulaglutide (Trulicity, Eli Lilly and Company) significantly improved HbA1C when added to ongoing type-2 diabetes treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, according to results from the phase 3b AWARD-10 trial. The data were published online in The Lancet Diabetes & Endocrinology…
Read more

Erdafitinib Wins Breakthrough Therapy Designation for Bladder Cancer

The FDA has granted a breakthrough therapy designation for erdafitinib (Janssen Pharmaceuticals) in the treatment of urothelial cancer, an often-aggressive disease with a grim prognosis that is seen most frequently in the bladder. It’s the sixth most common type of cancer in the U.S. The breakthrough…
Read more

FDA Expands Gilotrif Indication for Non–Small-Cell Lung Cancer

The FDA has approved a supplemental new drug application (sNDA) for afatinib (Gilotrif, Boehringer Ingelheim) for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) whose tumors have nonresistant epidermal growth factor receptor (EGFR) mutations as detected by…
Read more

Has Flu Season Peaked? Doctor Visits Fall for a 3rd Week

Influenza activity decreased in the United States during the week ending February 24, according to the Centers for Disease Control and Prevention (CDC). In week 8 of this trying flu season, the proportion of outpatient visits to doctors blamed on influenza-like illness (ILI) fell for the third straight…
Read more

Patent Board Denies Allergan, Mohawk Bid to Shield Restasis Patents

Allergan’s attempt to protect six Restasis patents by assigning them to the St. Regis Mohawk Tribe has hit a snag: The U.S. Patent Trial and Appeal Board (PTAB) has denied the tribe’s motion to terminate Mylan's patent challenge. "The PTAB's ruling reinforces our belief that Allergan's maneuvers…
Read more

FDA OKs Adcetris Label Expansion for Hodgkin’s Lymphoma

The FDA has approved brentuximab vedotin (Adcetris, Seattle Genetics, Inc.) in combination with chemotherapy in adult patients with previously untreated stage III or IV classical Hodgkin’s lymphoma. The approval is based on the successful outcome of the phase 3 ECHELON-1 clinical trial that compared…
Read more

Fluarix Quadrivalent Vaccine Now Indicated for Children as Young as 6 Months

The FDA’s Center for Biologics Evaluation and Research has expanded the indication for Fluarix Quadrivalent (influenza vaccine, GlaxoSmithKline) to include use in people 6 months of age and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses…
Read more

Study Finds 7% Birth Defect Rate in Babies Born to Moms With Zika

A pregnant woman who becomes ill from the Zika virus faces a 7% chance that her child will be born with birth defects, and that risk jumps to nearly 13% if she becomes ill during the first trimester, a study conducted in French territories in the Americas has concluded. The finding “emphasizes the…
Read more

Aimmune’s Peanut Allergy Drug Meets Main Goal

Aimmune Therapeutics, Inc., has announced that its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18% pre-market, Reuters reports. The positive trial data comes nearly four months after French drug developer DBV Technologies SA’s stick-on patch…
Read more

PhRMA: Analysis Finds Higher Outpatient Drug Spending at 340B Hospitals

An analysis commissioned by a pharmaceutical industry trade group found that hospitals participating in the 340B Drug Discount Program have higher per-patient outpatient pharmacy costs than their non-340B counterparts––indicating patients at 340B hospitals are prescribed more medicines, more expensive…
Read more

Large Study Finds Smokers at Greater Risk of Hearing Loss

Smoking is associated with increased risk of hearing loss, according to a study of more than 50,000 participants over eight years. Researchers analyzed data from annual health checkups, which included audio testing performed by a technician and a health-related lifestyle questionnaire completed by each…
Read more

World’s Smallest Mechanical Heart Valve Wins FDA Approval

The FDA has approved the world’s smallest mechanical heart valve to aid in the treatment of congenital defects in newborns. The 15-mm valve size was added to the existing Masters Series Mechanical Heart Valve with Hemodynamic Plus Sewing Cuff (St. Jude Medical). “While larger replacement heart valves…
Read more

Pages

  • « first
  • ‹ previous
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • next ›
  • last »
Facebook Twitter LinkedIn RSS Feed
  • Contact Us
  • Our History
  • Terms & Conditions of Use Agreement
  • Address and Subscription Changes
  • 2018 Editorial Calendar
  • 2018 Space and Material Due Dates
  • BPA Statement
  • Submitting Original Research
  • Submitting Viewpoints
  • Site Map
  • Contact Webmaster
  • P&T Community
© 2018 MediMedia, an ICON plc company. All rights reserved.